Stay updated with breaking news from Davide Moller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
David Moller joins as Chief Scientific Officer and Steve Bryant as Chief Business Officer, adding deep expertise to executive teamSEATTLE--(BUSINESS WIRE)--Variant Bio, a genomics-driven drug discovery company, is transitioning from a company that focused on identifying genomic variants that uncover the basis of dis...
Results support the development of PXL770 in a Phase 2 clinical program for ADPKD Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis
statistically significant vs. placebo* or baseline** (p 0.05) ^(p 0.08; 0.052) “There is a sizable overlap in the NASH patient population such that approximately 50% of NASH patients also have co-existing type 2 diabetes. PXL770 is one of the only therapies in development that has demonstrated the potential to treat NASH with specific use in patients with coexisting type 2 diabetes that are at higher risk for faster disease progression and for co-morbidities, including cardiovascular complications,” commented Pascale Fouqueray, MD, PhD, Executive Vice President, Clinical Development a...